SELLAS Life Sciences
Update in progressSLS (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
SELLAS Life Sciences Group is a late‑stage clinical biopharmaceutical company developing cancer therapies in the United States. Its lead candidate, galinpepimut-S (GPS), is a WT1‑targeted peptide immunotherapy, and SLS009 (tambiciclib) is a selective CDK9 inhibitor. The company collaborates with Merck to study GPS with pembrolizumab in a Phase 1/2 trial across multiple cancers, with GenFleet for GFH009, and with MSK for WT1 vaccine tech. HQ in New York.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.18
- Governance
- 0.08
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEODr. Angelos M. Stergiou M.D., ScD h.c.
- Employees13
- Websitesellaslifesciences.com
Identifiers
- ISINUS81642T2096
- FIGIBBG000VC77H7
- LEI549300VZIH50VYURLQ98
- CUSIP363256108
- CIK0001390478